Agios Pharmaceuticals (AGIO) Competitors $35.22 +1.47 (+4.34%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$35.22 +0.00 (+0.01%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AGIO vs. RVMD, LEGN, BBIO, AXSM, BPMC, TLX, ELAN, LNTH, NUVL, and CYTKShould you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Agios Pharmaceuticals vs. Revolution Medicines Legend Biotech BridgeBio Pharma Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Lantheus Nuvalent Cytokinetics Agios Pharmaceuticals (NASDAQ:AGIO) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends. Do analysts prefer AGIO or RVMD? Agios Pharmaceuticals presently has a consensus price target of $56.33, suggesting a potential upside of 59.97%. Revolution Medicines has a consensus price target of $66.25, suggesting a potential upside of 60.26%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Which has better earnings and valuation, AGIO or RVMD? Agios Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$36.50M55.28$673.72M$11.343.11Revolution Medicines$11.58M600.54-$436.37M-$3.59-11.52 Is AGIO or RVMD more profitable? Agios Pharmaceuticals has a net margin of 1,845.92% compared to Revolution Medicines' net margin of 0.00%. Agios Pharmaceuticals' return on equity of -2.51% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals1,845.92% -2.51% -2.26% Revolution Medicines N/A -33.67%-30.08% Does the MarketBeat Community favor AGIO or RVMD? Agios Pharmaceuticals received 399 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 75.83% of users gave Revolution Medicines an outperform vote while only 66.94% of users gave Agios Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAgios PharmaceuticalsOutperform Votes49066.94% Underperform Votes24233.06% Revolution MedicinesOutperform Votes9175.83% Underperform Votes2924.17% Which has more volatility & risk, AGIO or RVMD? Agios Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Do institutionals & insiders hold more shares of AGIO or RVMD? 94.3% of Revolution Medicines shares are owned by institutional investors. 4.9% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 8.0% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor AGIO or RVMD? In the previous week, Agios Pharmaceuticals had 4 more articles in the media than Revolution Medicines. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 4 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.73 beat Agios Pharmaceuticals' score of 0.12 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRevolution Medicines beats Agios Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGIO vs. The Competition Export to ExcelMetricAgios PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.02B$7.07B$5.81B$9.02BDividend YieldN/A2.77%4.77%3.84%P/E Ratio3.113.9221.5016.68Price / Sales55.28314.28453.1985.13Price / CashN/A67.8343.9637.32Price / Book1.316.757.654.65Net Income$673.72M$138.11M$3.18B$245.69M7 Day Performance6.01%-2.54%-1.95%-2.67%1 Month Performance3.39%-2.00%-0.23%-2.16%1 Year Performance18.25%-5.04%16.69%12.90% Agios Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGIOAgios Pharmaceuticals4.3439 of 5 stars$35.22+4.3%$56.33+60.0%+31.4%$2.02B$36.50M3.11390Earnings ReportShort Interest ↓RVMDRevolution Medicines4.5103 of 5 stars$40.67-1.6%$66.25+62.9%+41.7%$6.84B$11.58M-11.33250LEGNLegend Biotech2.594 of 5 stars$36.42+0.1%$79.50+118.3%-33.7%$6.65B$285.14M-38.341,800News CoveragePositive NewsBBIOBridgeBio Pharma4.7202 of 5 stars$34.90+10.6%$49.08+40.6%+7.9%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5266 of 5 stars$131.15-0.4%$147.13+12.2%+67.8%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines3.0033 of 5 stars$93.94-1.3%$123.83+31.8%+5.7%$5.97B$249.38M-44.52640Earnings ReportAnalyst UpgradeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.057 of 5 stars$11.26-3.4%$16.29+44.7%-31.9%$5.57B$4.42B28.159,300Analyst ForecastLNTHLantheus4.5803 of 5 stars$79.94-2.5%$131.86+64.9%+37.9%$5.56B$1.30B13.30700Analyst RevisionNews CoveragePositive NewsNUVLNuvalent2.1318 of 5 stars$77.93-3.7%$112.36+44.2%-3.7%$5.54BN/A-22.4640Upcoming EarningsInsider TradeCYTKCytokinetics4.1939 of 5 stars$46.16+10.9%$82.00+77.6%-34.3%$5.45B$7.53M-8.58250News CoverageHigh Trading Volume Related Companies and Tools Related Companies Revolution Medicines Alternatives Legend Biotech Alternatives BridgeBio Pharma Alternatives Axsome Therapeutics Alternatives Blueprint Medicines Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Elanco Animal Health Alternatives Lantheus Alternatives Nuvalent Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AGIO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGIO Stock Alerts